-

AHF Urges Top Moderna Shareholders to Divest Stock

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) sent letters to the top investors of Moderna, Inc. this week, urging them to divest from the vaccine maker in the interest of corporate social responsibility. After it accepted at least $2.5 billion in US taxpayer funding, Moderna priced its vaccine higher than any other manufacturer and has been unwilling to share the know-how and technology to increase global production.

AHF’s appeal to shareholders to release their holdings follows calls by some investors for Moderna to explain why its vaccines are priced so high and virtually unavailable in poorer countries. Moderna expects 2021 sales to be “between $15 billion and $18 billion,” according to a People’s Vaccine Alliance report. Additionally, the pharma company expects “about $18.5 billion in 2022 from contracts for its COVID-19 vaccine, and about $3.5 billion from potential additional purchases including booster candidates updated for variants,” according to Reuters.

“Moderna could be the poster child for corporate greed. And while we’ve come to expect this from drug companies – enough is enough. The world must not allow price-gouging on lifesaving commodities during a pandemic – a crisis that’s caused over 5.5 million global deaths,” said AHF Africa Bureau Chief Dr. Penninah Iutung. “Someone must set the example and put lives before profits—which is why we’re calling on investors to dump their Moderna shares and hit the vaccine manufacturer in the only place they care about – their pocketbook.”

In addition to pricing its vaccine so high it’s unattainable for most countries, Moderna has also refused to engage in meaningful negotiations with the US Government to share its technology with other vaccine makers, which would allow vaccines to be produced locally in lower-income countries. To date, only 1% of the nearly 10 billion global vaccine doses have gone to low-income countries. Barely 15% of people in Africa have received even one dose of a vaccine, compared to 84% and 74% for Canada and the United States, respectively.

“The world is entering the third year of living under the shroud of COVID-19 and is more than a year removed from when vaccines became available – there’s no reason why the majority of countries should still be struggling to get sufficient access to lifesaving doses,” added Terri Ford, Chief of Global Advocacy and Policy for AHF. “It’s sad that we’re left with only extreme measures, but even investors are now telling the world that Moderna’s greed must be curbed to meet the global need for vaccines. Today is trash day – stockholders must dump their Moderna shares immediately.”

AHF has led its Vaccinate Our World (VOW) campaign since early 2021 to push leaders of wealthy countries and vaccine manufacturers to expand vaccine access for resource-poor countries. Learn more by visiting the VOW website today. The list of top 10 institutional shareholders of Moderna is available here.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.6 million clients in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1.323.308.1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF
+1 323.308.1829
denys.nazarov@ahf.org

AIDS Healthcare Foundation


Release Versions

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1.323.308.1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF
+1 323.308.1829
denys.nazarov@ahf.org

Social Media Profiles
More News From AIDS Healthcare Foundation

Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the world’s largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around concerns that the initial Gilead-...

AHF to Commemorate 40 Years of Global Impact During Annual World AIDS Day Concert Celebration

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the world’s largest, non-profit public health organization providing direct HIV/AIDS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. The event, which is free and open to the public, is scheduled for the evening of Monday, November 30, 2026, at the Kia Forum in Inglewood, California. RSVP to AHFWAD.org for tickets. Commemorated annually...

Sexual Health Is Health: Testing, Treatment and Prevention for All, says AHF

LOS ANGELES--(BUSINESS WIRE)--As sexually transmitted infections continue to rise worldwide, AIDS Healthcare Foundation (AHF) marks World Sexual Health Day by calling on governments and health systems to expand access to prevention, testing, and treatment services for HIV and other STIs. Despite proven tools to prevent, diagnose, and treat HIV and other STIs, gaps in access continue to put millions of people at risk globally. With an estimated 1.2 million new HIV infections each year globally,...
Back to Newsroom